0001104659-16-155145.txt : 20161209 0001104659-16-155145.hdr.sgml : 20161209 20161107144735 ACCESSION NUMBER: 0001104659-16-155145 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics AG CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: C4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 BUSINESS PHONE: 43 (0)1 740 93-0 MAIL ADDRESS: STREET 1: LEBERSTRASSE 20 CITY: VIENNA STATE: C4 ZIP: 1110 CORRESP 1 filename1.htm

 

Nabriva Therapeutics AG

Leberstrasse 20

1110 Vienna, Austria

 

November 7, 2016

 

VIA EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C.  20549

 

Re:                             Nabriva Therapeutics AG

Registration Statement on Form F-3

File No. 333-214197

Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics AG (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333-214197), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 9, 2016, or as soon thereafter as practicable.

 

 

 

Very truly yours,

 

 

 

 

 

NABRIVA THERAPEUTICS AG

 

 

 

 

 

By:

/s/ Colin Broom

 

 

Name:

Colin Broom

 

 

Title:

Chief Executive Officer